San Francisco, CA, United States of America

Julie Hambleton

This inventor holds 11 USPTO granted patents and 16 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Compnay. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Julie Hambleton. Retrieved from https://idiyas.com/inventor/julie-hambleton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 16)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 16)

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 28(Granted Patents)

Location History:

South San Francisco, CA (US) (2018 - 2021)
San Francisco, CA (US) (2017 - 2023)

Company Filing History:

11 out of 77

Five Prime Therapeutics, Inc.

patents

5 out of 3,742

Bristol-Myers Squibb Compnay

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12465636 - METHOD OF MAKING AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIES (2025-11-11),

2. 11566076 - Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers (2023-01-31),

3. 11421034 - Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer (2022-08-23),

4. 11235059 - Afucosylated anti-FGFR2IIIB antibodies (2022-02-01),

5. 10975153 - Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) (2021-04-13),

6. 10730949 - Method of treating PVNS with anti-CSF1R antibodies (2020-08-04),

7. 10618967 - Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer (2020-04-14),

8. 10221244 - Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer (2019-03-05),

9. 10172937 - Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies (2019-01-08),

10. 10040858 - Anti-CSF1R antibodies for treating PVNS (2018-08-07),

11. 9765147 - Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer (2017-09-19),

Title: The Innovative Journey of Julie Hambleton

Introduction: Julie Hambleton, a pioneering inventor based in San Francisco, CA, has made significant contributions to the field of technology with her groundbreaking inventions.

Latest Patents: Julie Hambleton's latest patents include a cutting-edge wearable device that tracks health metrics in real-time and a revolutionary software application designed to streamline communication in the workplace.

Career Highlights: With a career spanning over two decades, Julie Hambleton has established herself as a leading figure in the tech industry. Her innovative solutions have garnered international recognition and have been instrumental in shaping the future of digital technology.

Collaborations: Throughout her career, Julie Hambleton has collaborated with top research institutions, leading universities, and renowned tech companies to further develop and implement her inventions. Her collaborative spirit has led to the creation of groundbreaking technologies that have transformed various industries.

Conclusion: Julie Hambleton's passion for innovation and her relentless pursuit of technological advancement continue to inspire aspiring inventors worldwide. Her remarkable achievements underscore her status as a trailblazer in the world of technology.

Profile summary based on public USPTO records.